Determinants of active surveillance uptake in a diverse population‐based cohort of men with low‐risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS)

Abstract

AbstractBackgroundActive surveillance (AS) is the preferred strategy for low‐risk prostate cancer (LRPC); however, limited data on determinants of AS adoption exist, particularly among Black men.MethodsBlack and White newly diagnosed (from January 2014 through June 2017) patients with LRPC ≤75 years of age were identified through metro‐Detroit and Georgia population‐based cancer registries and completed a survey evaluating factors influencing AS uptake.ResultsAmong 1688 study participants, 57% chose AS (51% of Black participants, 61% of White) over definitive treatment. In the unadjusted analysis, patient factors associated with initial AS uptake included older age, White race, and higher education. However, after adjusting for covariates, none of these factors was significant predictors of AS uptake. The strongest determinant of AS uptake was the AS recommendation by a urologist (adjusted prevalence ratio, 6.59, 95% CI, 4.84–8.97). Other factors associated with the decision to undergo AS included a shared patient–physician treatment decision, greater prostate cancer knowledge, and residence in metro‐Detroit compared with Georgia. Conversely, men whose decision was strongly influenced by the desire to achieve “cure” or “live longer” with treatment and those who perceived their LRPC diagnosis as more serious were less likely to choose AS.ConclusionsIn this contemporary sample, the majority of patients with newly diagnosed LRPC chose AS. Although the input from their urologists was highly influential, several patient decisional and psychological factors were independently associated with AS uptake. These data shed new light on potentially modifiable factors that can help further increase AS uptake among patients with LRPC.